DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells

European Journal of Immunology

Volumn 40, Issue 3, 2010, Pages 899-910

  Pudney, Victoria A ^a   Metheringham, Rachael L ^a   Gunn, Barbara ^a   Spendlove, Ian ^a   Ramage, Judith M ^a   Durrant, Lindy G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

CTL; Epitopes; Tumor immunity; Vaccination

Indexed keywords

DNA ANTIBODY; DNA VACCINE; EPITOPE; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIGEN PRESENTATION; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; FEMALE; HUMAN; KNOCKOUT MOUSE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77749245797     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200939857     Document Type: Article

References (44)

1. Zeh, H. J., Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A. and Yang, J. C., High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 1999. 162: 989-994.
2. Dutoit, V., Rubio-Godoy, V., Dietrich, P., Quiqueres, A., Schnuriger, V., Rimoldi, D., Lienard, D. et al., Heterogeneous T-cell response to MAGA10254-262: High avidity-specific cytolytic T lymphocytes show superior antitumour activity. Cancer Res. 2001. 61: 5850-5853.
3. Alexander-Miller, M. A., Leggatt, G. R. and Berzofsky, J. A., Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 1996. 93: 4102-4107.
4. Ayyoub, M., Rimoldi, D., Guillaume, P., Romero, P., Cerottini, J. C., Valmori, D. and Speiser, D., Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigenexpressing tumors in melanoma patients. Cancer Res. 2003. 63: 5601-5606.
5. Sedlik, C., Dadaglio, G., Saron, M. F., Deriaud, E., Rojas, M., Casal, S. I. and Leclerc, C., In vivo induction of a high-avidity, high-frequency cytotoxic Tlymphocyte response is associated with antiviral protective immunity. J. Virol. 2000. 74: 5769-5775.
6. Alexander-Miller, M. A., Leggatt, G. R., Sarin, A. and Berzofsky, J. A., Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 1996. 184: 485-492.
7. Kroger, C. J. and Alexander-Miller, M. A., Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter. Immunology 2007. 122: 167-178.
8. Maryanski, J. L., Pala, P., Cerottini, J. C. and MacDonald, H. R., Antigen recognition by H-2-restricted cytolytic T lymphocytes: inhibition of cytolysis by anti-CD8 monoclonal antibodies depends upon both concentration and primary sequence of peptide antigen. Eur. J. Immunol. 1988. 18: 1863-1866.
9. Sandberg, J. K., Franksson, L., Sundback, J., Michaelsson, J., Petersson, M., Achour, A., Wallin, R. P. A. et al., T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J. Immunol. 2000. 165: 25-33.
10. Oh, S., Hodge, J. W., Ahlers, J. D., Burke, D. S., Schlom, J. and Berzofsky, J. A., Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. 2003. 170: 2523-2530.
11. Xu, S., Koski, G. K., Faries, M., Bedrosian, I., Mick, R., Maeurer, M., Cheever, M. A. et al., Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J. Immunol. 2003. 171: 2251-2261.
12. Cawthon, A. G., Lu, H. and Alexander-Miller, M. A., Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8ab versus CD8aa expression. J. Immunol. 2001. 167: 2577-2584.
13. Hodge, J. W., Chakraborty, M., Kudo-Saito, C., Garnett, C. T. and Schlom, J., Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 2005. 174: 5994-6004.
14. Zaghouani, H., Steinman, R., Nonacs, R., Shah, H., Gerhard,W. and Bona, C., Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science 1993. 259: 224-227.
15. Billetta, R., Hollingdale, M. R. and Zanetti, M., Immunogenicity of an engineered internal image antibody. Proc. Natl. Acad. Sci. USA 1991. 88: 4713-4717.
16. Brumeanu, T. D., Swiggard, W. J., Steinman, R. M., Bona, C. A. and Zaghouani, H., Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus. J. Exp. Med. 1993. 178: 1795-1799.
17. Kuzu, Y., Kuzu, H., Zaghouani, H. and Bona, C., Priming of cytotoxic T lymphocytes at various stages of ontogeny with transfectoma cells expressing a chimeric Ig heavy chain gene bearing an influenza virus nucleoprotein peptide. Int. Immunol. 1993. 5: 1301-1307.
18. Zaghouani, H., Kuzu, Y., Kuzu, H., Brumeanu, T. D., Swiggard, W. J., Steinman, R. M. and Bona, C. A., Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin. Eur. J. Immunol. 1993. 23: 2746-2750.
19. Bot, A., Smith, D., Phillips, B., Bot, S., Bona, C. and Zaghouani, H., Immunologic control of tumors by in vivo Fc gamma receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation. J. Immunol. 2006. 176: 1363-1374.
20. Pritchard-Jones, K., Spendlove, I., Wilton, C., Whelan, J., Weeden, S., Lewis, I., Hale, J. et al., Immune responses to the 105AD7 human antiidiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br. J. Cancer 2005. 92: 1358-1365.
21. Amin, S., Robins, R. A., Maxwell-Armstrong, C. A., Scholefield, J. H. and Durrant, L. G., Vaccine-induced apoptosis: a novel clinical trial end point? Cancer Res. 2000. 60: 3132-3136.
22. Ullenhag, G. J., Spendlove, I.,Watson, N. F., Indar, A. A., Dube, M., Robins, R. A., Maxwell-Armstrong, C. et al., A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin. Cancer Res. 2006. 12: 7389-7396.
23. Durrant, L. G., Parsons, T., Moss, R., Spendlove, I., Carter, G. and Carr, F., Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses. Int. J. Cancer 2001. 92: 414-420.
24. Fanger, N. A.,Wardwell, K., Shen, L., Tedder, T. F. and Guyre, P. M., Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J. Immunol. 1996. 157: 541-548.
25. Dhodapkar, K. M., Kaufman, J. L., Ehlers, M., Banerjee, D. K., Bonvini, E., Koenig, S., Steinman, R. M. et al., Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA 2005. 102: 2910-2915.
26. Metheringham, R., Pudney, V., Gunn, B., Towey, M., Spendlove, I. and Durrant, L., Antibodies designed as effective cancer vaccines. mAbs 2009. 1: 71-85.
27. Kroger, C. J. and Alexander-Miller, M. A., Cutting edge: CD8+ T cell clones possess the potential to differentiate into both high- and low-avidity effector cells. J. Immunol. 2007. 179: 748-751.
28. De Palma, R., Marigo, I., Del Galdo, F., De Santo, C., Serafini, P., Cingarlini, S., Tuting, T. et al., Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes. Cancer. Res. 2004. 64: 8068-8076.
29. Powell, M. F., Stewart, T., Otvos, L., Jr., Urge, L., Gaeta, F. C., Sette, A., Arrhenius, T. et al., Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm. Res. 1993. 10: 1268-1273.
30. Bellone, M., Cantarella, D., Castiglioni, P., Crosti, M. C., Ronchetti, A., Moro, M., Garancini, M. P. et al., Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 2000. 165: 2651-2656.
31. Steitz, J., Bruck, J., Gambotto, A., Knop, J. and Tuting, T., Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther. 2002. 9: 208-213.
32. Bronte, V., Apolloni, E., Ronca, R., Zamboni, P., Overwijk, W.W., Surman, D. R., Restifo, N. P. and Zanovello, P., Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 2000. 60: 253-258.
33. Yamano, T., Kaneda, Y., Huang, S., Hiramatsu, S. H. and Hoon, D. S., Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 2006. 13: 194-202.
34. Kim, J. H., Chen, J., Majumder, N., Lin, H., Falo, L. D., Jr. and You, Z., 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity. Gene Ther. 2005. 12: 1517-1525.
35. Sutmuller, R. P., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N., Wildenberg, M. E., Allison, J. P., Toes, R. E. et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001. 194: 823-832.
36. Porgador, A., Irvine, K. R., Iwasaki, A., Barber, B. H., Restifo, N. P. and Germain, R. N., Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 1998. 188: 1075-1082.
37. Cho, J. H., Youn, J. W. and Sung, Y. C., Cross-priming as a predominant mechanism for inducing CD8(1) T cell responses in gene gun DNA immunization. J. Immunol. 2001. 167: 5549-5557.
38. Kim, P. S., Armstrong, T. D., Song, H., Wolpoe, M. E., Weiss, V., Manning, E. A., Huang, L. Q. et al., Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J. Clin. Invest. 2008. 118: 1700-1711.
39. Harbers, S. O., Crocker, A., Catalano, G., D'Agati, V., Jung, S., Desai, D. D. and Clynes, R., Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J. Clin. Invest. 2007. 117: 1361-1369.
40. Saenger, Y. M., Li, Y., Chiou, K. C., Chan, B., Rizzuto, G., Terzulli, S. L., Merghoub, T. et al., Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res. 2008. 68: 9884-9891.
41. Strawbridge, A. B. and Blum, J. S., Autophagy in MHC class II antigen processing. Curr. Opin. Immunol. 2007. 19: 87-92.
42. Bloom, M. B., Perry-Lalley, D., Robbins, P. F., Li, Y., el-Gamil, M., Rosenberg, S. A. and Yang, J. C., Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 1997. 185: 453-459.
43. Rotzschke, O., Falk, K., Stevanovic, S., Jung, G., Walden, P. and Rammensee, H. G., Exact prediction of a natural T cell epitope. Eur. J. Immunol. 1991. 21: 2891-2894.
44. Milich, D. R., Hughes, J. L., McLachlan, A., Thornton, G. B. and Moriarty, A., Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc. Natl. Acad. Sci. USA 1988. 85: 1610-1614.